Neurofilament Light ChainNCT07312994
Analysis of NfL and GFAP in Different Dietary Patterns
An observational study of Neurofilament Light Chain and Glial Fibrillary Acidic Protein, run by Salzburger Landeskliniken at 1 site in Austria.
Trial summary
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP. The primary research question is: Do vegan, vegetarian, or omnivorous diets influence NfL and GFAP levels? Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP
- How many people
- 300 participants
- Where
- 1 siteAustria
- Study dates
- 18 Dec 2025to Sep 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Young and healthy individuals aged between 18 and 40 years
Who may be able to join
- Healthy individuals who have followed a vegan, vegetarian, or omnivorous diet for at least one consecutive year
- Aged between 18 and 40 years
- Provision of written informed consent
Who cannot join
- Diagnose neurological disorders (e.g. neurodegenerative, inflammatory, autoimmune, infectious, vascular)
- Eating disorders
- Excessive alcohol consumption
- Pregnancy
- Recent moderate to severe infection (within the past 12 weeks) , including SARS-CoV-2
- Recent trauma, injury, or surgery (within the past 12 weeks)
- Significant BMI fluctuations (>5 points) within the last year
- Patients who have been using Proton pump inhibitors (PPIs) for an extended period (e.g., 1 month).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Austria1 site, 1 recruiting
- Recruiting
Christian-Doppler-Klinik
Salzburg, State of Salzburg, 5020
Fabio Rossini, MD, f.rossin@salk.at
About this study
Official title: Vegan, Vegeratian, or Omnivore: Dietary Effects on the Brain Tissue Biomarkers
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
The primary research question is: Do vegan, vegetarian, or omnivorous diets influence NfL and GFAP levels?
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet, Vegetarian Diet
- Medical subject headings
- Charcot-Marie-Tooth disease, Type 1F
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Omnivore | Not described | |
| Vegan | Not described | |
| Vegetarian | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood levels of the following biomarkers: neurofilament light chain (NfL) in pg/mL, glial fibrillary acidic protein (GFAP) in pg/mL.
Measured: Once at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Dec 2025
- Study start18 Dec 2025
- Primary completionApr 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurofilament Light ChainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Salzburger Landeskliniken
- Sponsor type
- University, hospital or other
- Collaborators
- Medizinische Einrichtungen der Universität Düsseldorf, Universität zu Köln, Universitätsklinkum Münster - Medizinische Klinik und Poliklinik B
- Responsible party
- Principal investigator, Tobias Moser, Salzburger Landeskliniken
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07312994
- Sponsor's protocol ID
- 1119/2025
- Status last verified
- Dec 2025
- First submitted
- 9 Dec 2025
- Last updated
- 31 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vegan, Vegeratian, or Omnivore: Dietary Effects on the Brain Tissue Biomarkers
- ClinicalTrials.gov ID
- NCT07312994
- Acronym / sponsor ID
- 1119/2025
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet, Vegetarian Diet
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Salzburger LandesklinikenUniversity, hospital or other
- Collaborators
- Medizinische Einrichtungen der Universität Düsseldorf, Universität zu Köln, Universitätsklinkum Münster - Medizinische Klinik und Poliklinik B
- Study start
- 18 Dec 2025 (actual)
- Primary completion
- Apr 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 31 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
The primary research question is: Do vegan, vegetarian, or omnivorous diets influence NfL and GFAP levels?
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Omnivore | – | – |
| Vegan | – | – |
| Vegetarian | – | – |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Young and healthy individuals aged between 18 and 40 years
Key inclusion criteria (3 listed)
- Healthy individuals who have followed a vegan, vegetarian, or omnivorous diet for at least one consecutive year
- Aged between 18 and 40 years
- Provision of written informed consent
Key exclusion criteria (8 listed)
- Diagnose neurological disorders (e.g. neurodegenerative, inflammatory, autoimmune, infectious, vascular)
- Eating disorders
- Excessive alcohol consumption
- Pregnancy
- Recent moderate to severe infection (within the past 12 weeks) , including SARS-CoV-2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Blood levels of the following biomarkers: neurofilament light chain (NfL) in pg/mL, glial fibrillary acidic protein (GFAP) in pg/mL.
Time frame: Once at baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Neurofilament Light Chain
Not yet recruiting
Impact of Exercise Training on Serum Neurofilament Light Chain (NfL), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis
Multiple Sclerosis, Exercise
Enrolling by invitationObservational study
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
Fatigue in Multiple Sclerosis, Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurofilament Light Chain and Glial Fibrillary Acidic Protein, run by Salzburger Landeskliniken at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tobias Moser, Prof. (+435725534720, t.moser@salk.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood levels of the following biomarkers: neurofilament light chain (NfL) in pg/mL, glial fibrillary acidic protein (GFAP) in pg/mL. (time frame: Once at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025; AzTrials last refreshed its copy on 26 Oct 2026.